Cargando…
Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice
Hypertension is one of the common causes of pathological cardiac hypertrophy and a major risk for morbidity and mortality of cardiovascular diseases worldwide. Ubiquitin-Specific Protease 7 (USP7), the first identified deubiquitinating enzymes, participated in a variety of biological processes, such...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640964/ https://www.ncbi.nlm.nih.gov/pubmed/36386139 http://dx.doi.org/10.3389/fphar.2022.1021361 |
_version_ | 1784825983522570240 |
---|---|
author | Gu, Yu-Hui Ren, Kai-Wen Wang, Yu Wang, Shi-Hao Yu, Xiao-Hong Xu, Li-Wen Li, Hui-Hua Bi, Hai-Lian |
author_facet | Gu, Yu-Hui Ren, Kai-Wen Wang, Yu Wang, Shi-Hao Yu, Xiao-Hong Xu, Li-Wen Li, Hui-Hua Bi, Hai-Lian |
author_sort | Gu, Yu-Hui |
collection | PubMed |
description | Hypertension is one of the common causes of pathological cardiac hypertrophy and a major risk for morbidity and mortality of cardiovascular diseases worldwide. Ubiquitin-Specific Protease 7 (USP7), the first identified deubiquitinating enzymes, participated in a variety of biological processes, such as cell proliferation, DNA damage response, tumourigenesis, and apoptosis. However, its role and mechanism in cardiac remodeling remain unclear. Here, our data indicated that USP7 expression was increased during Ang II-induced cardiac hypertrophy and remodeling in mice and humans with heart failure, while the administration of its inhibitor p22077 attenuated cardiac hypertrophy, cardiac fibrosis, inflammation, and oxidase stress. Mechanistically, the administration of p22077 inhibited the multiple signaling pathways, including AKT/ERK, TGF-β/SMAD2/Collagen I/Collagen III, NF-κB/NLRP3, and NAPDH oxidases (NOX2 and NOX4). Taken together, these findings demonstrate that USP7 may be a new therapeutic target for hypertrophic remodeling and HF. |
format | Online Article Text |
id | pubmed-9640964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96409642022-11-15 Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice Gu, Yu-Hui Ren, Kai-Wen Wang, Yu Wang, Shi-Hao Yu, Xiao-Hong Xu, Li-Wen Li, Hui-Hua Bi, Hai-Lian Front Pharmacol Pharmacology Hypertension is one of the common causes of pathological cardiac hypertrophy and a major risk for morbidity and mortality of cardiovascular diseases worldwide. Ubiquitin-Specific Protease 7 (USP7), the first identified deubiquitinating enzymes, participated in a variety of biological processes, such as cell proliferation, DNA damage response, tumourigenesis, and apoptosis. However, its role and mechanism in cardiac remodeling remain unclear. Here, our data indicated that USP7 expression was increased during Ang II-induced cardiac hypertrophy and remodeling in mice and humans with heart failure, while the administration of its inhibitor p22077 attenuated cardiac hypertrophy, cardiac fibrosis, inflammation, and oxidase stress. Mechanistically, the administration of p22077 inhibited the multiple signaling pathways, including AKT/ERK, TGF-β/SMAD2/Collagen I/Collagen III, NF-κB/NLRP3, and NAPDH oxidases (NOX2 and NOX4). Taken together, these findings demonstrate that USP7 may be a new therapeutic target for hypertrophic remodeling and HF. Frontiers Media S.A. 2022-10-25 /pmc/articles/PMC9640964/ /pubmed/36386139 http://dx.doi.org/10.3389/fphar.2022.1021361 Text en Copyright © 2022 Gu, Ren, Wang, Wang, Yu, Xu, Li and Bi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Gu, Yu-Hui Ren, Kai-Wen Wang, Yu Wang, Shi-Hao Yu, Xiao-Hong Xu, Li-Wen Li, Hui-Hua Bi, Hai-Lian Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice |
title | Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice |
title_full | Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice |
title_fullStr | Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice |
title_full_unstemmed | Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice |
title_short | Administration of USP7 inhibitor P22077 inhibited cardiac hypertrophy and remodeling in Ang II-induced hypertensive mice |
title_sort | administration of usp7 inhibitor p22077 inhibited cardiac hypertrophy and remodeling in ang ii-induced hypertensive mice |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640964/ https://www.ncbi.nlm.nih.gov/pubmed/36386139 http://dx.doi.org/10.3389/fphar.2022.1021361 |
work_keys_str_mv | AT guyuhui administrationofusp7inhibitorp22077inhibitedcardiachypertrophyandremodelinginangiiinducedhypertensivemice AT renkaiwen administrationofusp7inhibitorp22077inhibitedcardiachypertrophyandremodelinginangiiinducedhypertensivemice AT wangyu administrationofusp7inhibitorp22077inhibitedcardiachypertrophyandremodelinginangiiinducedhypertensivemice AT wangshihao administrationofusp7inhibitorp22077inhibitedcardiachypertrophyandremodelinginangiiinducedhypertensivemice AT yuxiaohong administrationofusp7inhibitorp22077inhibitedcardiachypertrophyandremodelinginangiiinducedhypertensivemice AT xuliwen administrationofusp7inhibitorp22077inhibitedcardiachypertrophyandremodelinginangiiinducedhypertensivemice AT lihuihua administrationofusp7inhibitorp22077inhibitedcardiachypertrophyandremodelinginangiiinducedhypertensivemice AT bihailian administrationofusp7inhibitorp22077inhibitedcardiachypertrophyandremodelinginangiiinducedhypertensivemice |